WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H597905
CAS#: 206269-27-4
Description: Levovirin is a monocyclic L-nucleosides with type 1 cytokine-inducing activity. Levovirin is the L-enantiomer of Ribavirin with similar immunomodulatory activity but does not have direct antiviral activity or hemolytic anemia.
Hodoodo Cat#: H597905
Name: Levovirin
CAS#: 206269-27-4
Chemical Formula: C8H12N4O5
Exact Mass: 244.08
Molecular Weight: 244.207
Elemental Analysis: C, 39.35; H, 4.95; N, 22.94; O, 32.76
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Levovirin; L-Ribavirin; ICN17261; ICN 17261; ICN-17261;
IUPAC/Chemical Name: 1-((2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboxamide
InChi Key: IWUCXVSUMQZMFG-RGDLXGNYSA-N
InChi Code: InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m0/s1
SMILES Code: O=C(C1=NN([C@@H]2[C@H]([C@H]([C@H](CO)O2)O)O)C=N1)N
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 244.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Huang Y, Ostrowitzki S, Hill G, Navarro M, Berger N, Kopeck P, Mau CI, Alfredson T, Lal R. Single- and multiple-dose pharmacokinetics of levovirin valinate hydrochloride (R1518) in healthy volunteers. J Clin Pharmacol. 2005 May;45(5):578-88. PubMed PMID: 15831782.
2: Fang C, Srivastava P, Lin CC. Effect of ribavirin, levovirin and viramidine on liver toxicological gene expression in rats. J Appl Toxicol. 2003 Nov-Dec;23(6):453-9. PubMed PMID: 14635270.
3: Lin CC, Luu T, Lourenco D, Yeh LT, Lau JY. Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. J Antimicrob Chemother. 2003 Jan;51(1):93-9. PubMed PMID: 12493792.
4: Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drugs. 2002 May;3(5):680-3. Review. PubMed PMID: 12090539.
5: Lin CC, Lau JY. Specific, sensitive and accurate LC-MS/MS method for the measurement of levovirin in rat and monkey plasma. J Pharm Biomed Anal. 2002 Sep 5;30(2):239-46. PubMed PMID: 12191708.
6: Li F, Hong L, Mau CI, Chan R, Hendricks T, Dvorak C, Yee C, Harris J, Alfredson T. Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. J Pharm Sci. 2006 Jun;95(6):1318-25. PubMed PMID: 16634069.
7: Hofmann WP, Polta A, Herrmann E, Mihm U, Kronenberger B, Sonntag T, Lohmann V, Schönberger B, Zeuzem S, Sarrazin C. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology. 2007 Mar;132(3):921-30. Epub 2006 Dec 3. PubMed PMID: 17383421.
8: Soota K, Maliakkal B. Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection. World J Gastroenterol. 2014 Nov 21;20(43):16184-90. doi: 10.3748/wjg.v20.i43.16184. Review. PubMed PMID: 25473172; PubMed Central PMCID: PMC4239506.
9: Singh V, Somvanshi P. Structural modeling of the NS 3 helicase of Tick-borne encephalitis virus and their virtual screening of potent drugs using molecular docking. Interdiscip Sci. 2009 Sep;1(3):168-72. doi: 10.1007/s12539-009-0039-4. Epub 2009 Aug 7. PubMed PMID: 20640834.
10: Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis. 2004;24 Suppl 2:97-104. Review. PubMed PMID: 15346252.
11: Plöckinger U, Krüger D, Bergk A, Weich V, Wiedenmann B, Berg T. Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. Am J Gastroenterol. 2007 Dec;102(12):2724-31. Epub 2007 Jul 27. PubMed PMID: 17662104.
12: Mihm U, Hofmann WP, Welsch C, Polta A, Lengauer T, Zeuzem S, Sarrazin C, Herrmann E. Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome. J Viral Hepat. 2010 Mar;17(3):217-21. doi: 10.1111/j.1365-2893.2009.01171.x. Epub 2009 Sep 15. PubMed PMID: 19758279.
